Inducible apoptosis as a safety switch for adoptive cell therapy

New England Journal of Medicine

Volumn 365, Issue 18, 2011, Pages 1673-1683

  Di Stasi, Antonio ^a   Tey, Siok Keen ^a   Dotti, Gianpietro ^a   Fujita, Yuriko ^a   Kennedy Nasser, Alana ^a   Martinez, Caridad ^a   Straathof, Karin ^a   Liu, Enli ^a   Durett, April G ^a   Grilley, Bambi ^a   Liu, Hao ^a   Cruz, Conrad R ^a   Savoldo, Barbara ^a   Gee, Adrian P ^a   Schindler, John ^b   Krance, Robert A ^a   Heslop, Helen E ^a   Spencer, David M ^a   Rooney, Cliona M ^a   Brenner, Malcolm K ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 1903; CASPASE 9; IMMUNOLOGIC AGENT; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HUMAN; LEUKEMIA RELAPSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL DEPLETION;

EID: 80455162464     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1106152     Document Type: Article

References (31)

1. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-8. (Pubitemid 351253699)
2. Williams DA, Keating A. Enhancing research in regenerative medicine. Blood 2010;116:866-7.
3. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9. (Pubitemid 32467049)
4. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83.
5. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010;363:1918-27.
6. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24. (Pubitemid 27421983)
7. Tiberghien P, Reynolds CW, Keller J, et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994;84:1333-41.
8. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a nonrandomised phase I-II study. Lancet Oncol 2009;10:489-500.
9. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplexthymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72. (Pubitemid 32061243)
10. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of genemodified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23. (Pubitemid 26057556)
11. Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther 1999;10:2273-85. (Pubitemid 29459838)
12. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science 1993;262:1019-24. (Pubitemid 24035037)
13. Amrolia PJ, Mucciolo-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006;108:1797-808. (Pubitemid 44394986)
14. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T-cells without loss of antiviral or antileukemic responses. Blood 2003;102:2292-9. [Erratum, Blood 2004;104:1605.] (Pubitemid 37122412)
15. Donnelly ML, Luke G, Mehrotra A, et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip.' J Gen Virol 2001;82:1013-25. (Pubitemid 32454602)
16. Quintarelli C, Vera JF, Savoldo B, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumorspecific cytotoxic T lymphocytes. Blood 2007;110:2793-802. (Pubitemid 350006931)
17. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54. (Pubitemid 40720769)
18. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-24. (Pubitemid 47055386)
19. Clackson T, Yang W, Rozamus LW, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A 1998;95:10437-42. (Pubitemid 28413085)
20. Zhou LJ, Ord DC, Hughes AL, Tedder TF. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes: conservation of the extensive cytoplasmic domain. J Immunol 1991;147:1424-32.
21. Akatsuka Y, Martin EG, Madonik A, Barsoukov AA, Hansen JA. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 1999;53:122-34. (Pubitemid 29089942)
22. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dosefinding trials. Cancer Chemother Pharmacol 1998;41:429-36. (Pubitemid 28140705)
23. Iuliucci JD, Oliver SD, Morley S, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 2001;41:870-9. (Pubitemid 32692098)
24. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007;109:4708-15. (Pubitemid 46827762)
25. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-707. (Pubitemid 46827761)
26. Mercier-Letondal P, Deschamps M, Sauce D, et al. Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T-cell-depleted marrow graft: an altered immune response? Hum Gene Ther 2008;19:937-50.
27. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
28. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-8.
29. Pollok KE, van der Loo JC, Cooper RJ, Kennedy L, Williams DA. Costimulation of transduced T lymphocytes via T-cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum Gene Ther 1999;10:2221-36. (Pubitemid 29416301)
30. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925-35.
31. Ramos CA, Asgari Z, Liu E, et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 2010;28:1107-15.